MA51664B1 - Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide - Google Patents
Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amideInfo
- Publication number
- MA51664B1 MA51664B1 MA51664A MA51664A MA51664B1 MA 51664 B1 MA51664 B1 MA 51664B1 MA 51664 A MA51664 A MA 51664A MA 51664 A MA51664 A MA 51664A MA 51664 B1 MA51664 B1 MA 51664B1
- Authority
- MA
- Morocco
- Prior art keywords
- cyclopropylmethyl
- isoxazole
- pyrimidin
- difluoro
- cyclopropyl
- Prior art date
Links
- OBSRDFSSNGPUIY-UHFFFAOYSA-N 1-pyrimidin-2-ylcyclopropan-1-amine Chemical compound N=1C=CC=NC=1C1(N)CC1 OBSRDFSSNGPUIY-UHFFFAOYSA-N 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title abstract 2
- 102100022716 Atypical chemokine receptor 3 Human genes 0.000 title 1
- 101000678890 Homo sapiens Atypical chemokine receptor 3 Proteins 0.000 title 1
- 239000013078 crystal Substances 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
L'invention concerne des formes cristallines de l'acide (3s,4s)-1- cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]- amino}-piperidine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)- amide ; des procédés pour leur préparation, et des compositions pharmaceutiques contenant de telles formes cristallines. Le composé agit en tant que modulateur du récepteur cxcr7 et est donc utile pour le traitement du cancer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2018051938 | 2018-01-26 | ||
| PCT/EP2019/051819 WO2019145460A1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-{[5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino}-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51664A MA51664A (fr) | 2021-05-05 |
| MA51664B1 true MA51664B1 (fr) | 2024-05-31 |
Family
ID=65139016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51664A MA51664B1 (fr) | 2018-01-26 | 2019-01-25 | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11339148B2 (fr) |
| EP (1) | EP3743422B1 (fr) |
| JP (1) | JP7076010B2 (fr) |
| KR (1) | KR102502046B1 (fr) |
| CN (1) | CN111683945B (fr) |
| AU (1) | AU2019212888B8 (fr) |
| BR (1) | BR112020015024A2 (fr) |
| CA (1) | CA3088478A1 (fr) |
| CL (1) | CL2020001928A1 (fr) |
| EA (1) | EA202091746A1 (fr) |
| ES (1) | ES2976567T3 (fr) |
| HR (1) | HRP20240552T1 (fr) |
| HU (1) | HUE066704T2 (fr) |
| IL (1) | IL276227B2 (fr) |
| MA (1) | MA51664B1 (fr) |
| MX (1) | MX392844B (fr) |
| MY (1) | MY206631A (fr) |
| PH (1) | PH12020551121A1 (fr) |
| PL (1) | PL3743422T3 (fr) |
| RS (1) | RS65594B1 (fr) |
| SG (1) | SG11202006943TA (fr) |
| TW (1) | TWI822724B (fr) |
| UA (1) | UA125327C2 (fr) |
| WO (1) | WO2019145460A1 (fr) |
| ZA (1) | ZA202005286B (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102497095B1 (ko) | 2016-07-28 | 2023-02-06 | 이도르시아 파마슈티컬스 리미티드 | 피페리딘 cxcr7 수용체 조절제 |
| WO2021084068A1 (fr) | 2019-10-31 | 2021-05-06 | Idorsia Pharmaceuticals Ltd | Combinaison d'un antagoniste de cxcr7 avec un modulateur du récepteur s1p1 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2507501C (fr) | 2002-11-27 | 2011-10-04 | Incyte Corporation | Derives de la 3-aminopyrrolidine modulateurs des recepteurs de la chemoquine |
| TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
| WO2005032490A2 (fr) | 2003-10-08 | 2005-04-14 | Bristol-Myers Squibb Company | Diamines cycliques et derives comme inhibiteurs du facteur xa |
| EP1853586B1 (fr) | 2005-02-18 | 2013-07-24 | AstraZeneca AB | Composés antibactériens dérivés de pipéridine |
| WO2009011850A2 (fr) * | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Nouveaux composés thérapeutiques |
| WO2012168315A1 (fr) | 2011-06-09 | 2012-12-13 | Boehringer Ingelheim International Gmbh | Pipéridines substituées à titre de modulateurs de gpr119 pour le traitement des troubles métaboliques |
| WO2013084241A1 (fr) | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Composés inhibiteurs de rénine |
| AR091516A1 (es) * | 2012-06-22 | 2015-02-11 | Actelion Pharmaceuticals Ltd | Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida |
| KR102196374B1 (ko) * | 2012-11-29 | 2020-12-31 | 케모센트릭스, 인크. | Cxcr7 길항제 |
| HUE036649T2 (hu) | 2013-05-30 | 2018-07-30 | Idorsia Pharmaceuticals Ltd | CXCR7 receptor modulátorok |
| EA029901B1 (ru) | 2013-09-04 | 2018-05-31 | Бристол-Майерс Сквибб Компани | Соединения для применения в качестве иммуномодуляторов |
| CU24362B1 (es) | 2013-09-06 | 2018-10-04 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| WO2015044900A1 (fr) | 2013-09-27 | 2015-04-02 | Aurigene Discovery Technologies Limited | Composés immunomodulateurs thérapeutiques |
| US20170253601A1 (en) * | 2014-09-10 | 2017-09-07 | Epizyme, Inc. | Substituted Pyrrolidine Compounds |
| JP2017528464A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム，インコーポレイティド | 置換ピペリジン化合物 |
| WO2016087370A1 (fr) | 2014-12-01 | 2016-06-09 | Actelion Pharmaceuticals Ltd | Modulateurs du récepteur cxcr7 |
| KR102497095B1 (ko) * | 2016-07-28 | 2023-02-06 | 이도르시아 파마슈티컬스 리미티드 | 피페리딘 cxcr7 수용체 조절제 |
-
2019
- 2019-01-25 TW TW108102825A patent/TWI822724B/zh active
- 2019-01-25 CN CN201980010015.7A patent/CN111683945B/zh active Active
- 2019-01-25 UA UAA202005451A patent/UA125327C2/uk unknown
- 2019-01-25 MA MA51664A patent/MA51664B1/fr unknown
- 2019-01-25 MY MYPI2020003778A patent/MY206631A/en unknown
- 2019-01-25 JP JP2020560586A patent/JP7076010B2/ja active Active
- 2019-01-25 US US16/964,885 patent/US11339148B2/en active Active
- 2019-01-25 KR KR1020207024352A patent/KR102502046B1/ko active Active
- 2019-01-25 WO PCT/EP2019/051819 patent/WO2019145460A1/fr not_active Ceased
- 2019-01-25 BR BR112020015024-0A patent/BR112020015024A2/pt unknown
- 2019-01-25 ES ES19701240T patent/ES2976567T3/es active Active
- 2019-01-25 EA EA202091746A patent/EA202091746A1/ru unknown
- 2019-01-25 IL IL276227A patent/IL276227B2/en unknown
- 2019-01-25 RS RS20240646A patent/RS65594B1/sr unknown
- 2019-01-25 HU HUE19701240A patent/HUE066704T2/hu unknown
- 2019-01-25 HR HRP20240552TT patent/HRP20240552T1/hr unknown
- 2019-01-25 PL PL19701240.4T patent/PL3743422T3/pl unknown
- 2019-01-25 MX MX2020007881A patent/MX392844B/es unknown
- 2019-01-25 SG SG11202006943TA patent/SG11202006943TA/en unknown
- 2019-01-25 EP EP19701240.4A patent/EP3743422B1/fr active Active
- 2019-01-25 AU AU2019212888A patent/AU2019212888B8/en active Active
- 2019-01-25 CA CA3088478A patent/CA3088478A1/fr active Pending
-
2020
- 2020-07-23 CL CL2020001928A patent/CL2020001928A1/es unknown
- 2020-07-24 PH PH12020551121A patent/PH12020551121A1/en unknown
- 2020-08-25 ZA ZA2020/05286A patent/ZA202005286B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53124B1 (fr) | Agents de dégradation sélectifs des récepteurs des oestrogènes | |
| MA56508B1 (fr) | Inhibiteur de l'egfr pour le traitement du cancer | |
| MA51620B1 (fr) | Analogues de dihydrobenzofurane et d'inden en tant qu'inhibiteurs de sarcomes cardiaques | |
| TN2014000147A1 (fr) | Derives de (4-phenylimidazol-2-yl) ethylamine utiles comme modulateurs de canal sodique | |
| TN2011000316A1 (fr) | Derives de sulfonamides | |
| MA42811B1 (fr) | Dérivés d'indole monosubstitués ou disubstitués utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue | |
| MA31419B1 (fr) | Derives de pyridine | |
| MA35601B1 (fr) | Pyrrolotriazines substituées par hydroxyméthylaryle utilisées comme inhibiteurs d'alk1 | |
| MA39582B1 (fr) | Composés de 6,7-dihydropyrazolo [1,5-?]pyrazin -4 (5h)-one et leur utilisation en tant que modulateurs négatifs allostériques des récepteurs métabotropiques du glutamate | |
| MA33132B1 (fr) | Derives pyrazole utilises comme antagonistes du recepteur ccr4 | |
| MA33533B1 (fr) | Compositions pharmaceutiques pour le traitement du cancer et d'autres maladies ou troubles | |
| MA47469B1 (fr) | Dérivés 2-(3-(1h-benzo[d]imidazol-1-yl)propyl)pipéridin-3-ol et composés similaires en tant q'inhibiteurs prs pour le traitement du cancer | |
| EP4663190A3 (fr) | Agonistes du récepteur muscarinique | |
| MA49127B1 (fr) | Dérivés d'indole n-substitués | |
| MA51664B1 (fr) | Formes cristallines de l'antagoniste du récepteur cxcr7 d'acide (3s,4s)-1-cyclopropylméthyl-4-([5-(2,4-difluoro-phényl)-isoxazole-3-carbonyl]-amino)-pipéridine-3-carboxylique (1-pyrimidin-2-yl-cyclopropyl)-amide | |
| MA70477B1 (fr) | Composés amido hétéroaromatiques utiles dans le traitement de maladies hépatiques | |
| MA30523B1 (fr) | Compose tricylique et utilisation pharmaceutique de celui-ci | |
| EA202092326A1 (ru) | Производные буметанида для лечения гипергидроза | |
| MA43913B1 (fr) | Modulateurs allostériques positifs du récepteur m1 muscarinique | |
| MX2023004008A (es) | Derivados de tetrazol como inhibidores de trpa1. | |
| MA29950B1 (fr) | Nouveau derive de la pleuromutiline et son utilisation | |
| MA52375A1 (fr) | Inhibiteurs de cdk8/19 | |
| CR20220668A (es) | Derivados de tetrazol como inhibidores de trpa1 | |
| MX2025006978A (es) | Compuestos heterociclicos y usos de los mismos | |
| MX2022016357A (es) | Derivados de tetrazol como inhibidores de trpa1. |